J Breast Cancer.  2016 Dec;19(4):465-465. 10.4048/jbc.2016.19.4.465.

Comment to “Patients with Concordant Triple-Negative Phenotype between Primary Breast Cancers and Corresponding Metastases Have Poor Prognosis”

• Altundag K

• KMID: 2362935
• DOI: http://doi.org/10.4048/jbc.2016.19.4.465

Abstract

No abstract available.

MeSH Terms

Breast*
Neoplasm Metastasis*
Phenotype*

Reference

1. Shin HC, Han W, Moon HG, Park IA, Noh DY. Patients with concordant triple-negative phenotype between primary breast cancers and corresponding metastases have poor prognosis. J Breast Cancer. 2016; 19:268–274.

2. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010; 28:2784–2795.

3. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer. 2007; 109:25–32.

4. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triplenegative phenotype: a population-based study from the California cancer Registry. Cancer. 2007; 109:1721–1728.